Simon J.HSIN-YUN SUNLeong H.N.Barez M.Y.C.Huang P.-Y.Talwar D.Wang J.-H.Mansor M.Wahjuprajitno B.Patel A.Wittayachanyapong S.Sany B.S.M.Lin S.-F.Dimopoulos G.2020-12-292020-12-2920130933-7407https://www.scopus.com/inward/record.uri?eid=2-s2.0-84886288504&doi=10.1111%2fmyc.12085&partnerID=40&md5=aa0fde63a7db1947bd70d6540d2832c5https://scholars.lib.ntu.edu.tw/handle/123456789/535399We summarise a recent meeting, sponsored by Pfizer Inc., where experts in Asia shared their clinical experience in managing IC. The echinocandins have demonstrated good activity against non-albicans infections and also azole-resistant strains, both preclinically and in recent clinical trials. As well as proving efficacious, echinocandins have a favourable safety profile and are well tolerated, including among inpatient subpopulations, such as transplant recipients and those with renal or hepatic dysfunction. In addition the echinocandins generally have minimal drug-drug interactions, unlike the oral azoles, which have multiple effects on cytochrome P450-mediated drug metabolism. Echinocandins are characterised by a good safety profile, few drug-drug interactions and good susceptibilities. With the increase in potentially azole-resistant non-albicans infections, echinocandins may become the first-line treatment of choice for many patients. ? 2013 Blackwell Verlag GmbH.[SDGs]SDG3amphotericin B; anidulafungin; caspofungin; cytochrome P450; fluconazole; host factor; micafungin; abdominal pain; antifungal activity; antifungal susceptibility; area under the curve; Candida albicans; candidemia; critically ill patient; diarrhea; disease predisposition; drug clearance; drug efficacy; drug protein binding; drug safety; fever; fungus growth; graft recipient; hematopoietic stem cell transplantation; human; iatrogenic disease; in vitro study; infection risk; invasive candidiasis; maximum plasma concentration; minimum inhibitory concentration; nausea; phlebitis; priority journal; review; time to maximum plasma concentration; vomiting; candidaemia; critically ill; Echinocandins; Antifungal Agents; Candidiasis, Invasive; Echinocandins; Humans; World Healthreview10.1111/myc.1208523647521